Retlirafusp alfa with chemoradiotherapy for unresectable esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called retlirafusp alfa combined with standard chemoradiotherapy for people with esophageal cancer that cannot be surgically removed. The goal is to see if this combination is safe and effective in shrinking tumors and improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of esophageal squamous cell carcinoma that is locally advanced and cannot be removed by surgery.
- You must not have received any prior treatment for this cancer, including radiation, chemotherapy, or surgery.
- You must be between 18 and 75 years old and in good general health (ECOG performance status 0-1).
- You must have adequate bone marrow, liver, and kidney function as shown by recent blood tests.
- You must not have active autoimmune disease, uncontrolled heart disease, or active infections such as HIV, hepatitis B or C, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether detailed scans taken before treatment can predict how well chemo and immunotherapy will work for advanced esophageal cancer. The goal is to improve treatment planning and potentially reduce side effects by personalizing care.
This trial tests a new approach for people with a certain type of esophageal cancer. Instead of surgery right away, you would receive chemotherapy, radiation, and an immunotherapy drug called adebrelimab. After that, doctors will closely watch your cancer to see if it's gone. The goal is to avoid surgery if the treatment works well.
This trial tests a new drug (retlirafusp alfa) combined with standard chemotherapy given before surgery to treat esophageal squamous cell carcinoma—a type of cancer in the food tube. The goal is to shrink the tumor before removal and improve outcomes.
This trial tests a new drug called retlirafusp alfa combined with chemotherapy as a treatment before and after surgery for a specific type of stomach cancer. It aims to see if this combination is safe and effective for patients whose cancer has a high level of a certain protein (CPS > 5) and is not driven by HER2.
This trial tests a short course of radiation combined with two drugs (raltitrexed and tislelizumab) for people with esophageal cancer that has returned after standard treatment. The goal is to see if these combinations can shrink tumors and improve survival.
This trial tests a personalized approach using MRI guidance for chemoradiotherapy combined with immunotherapy for limited advanced esophageal squamous cell cancer that cannot be surgically removed or has spread only to nearby lymph nodes. It aims to improve treatment effectiveness while reducing side effects.
Hear when a new Esophageal Squamous Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.